SOLID SCIENCE - NEAR TERM
Gene therapy is one of the hottest growth areas in biotech with about $10 Billion invested annually over the last several years.
Cellastra is targeting unmet needs in Long COVID, Surgery & Burn Care. The Long COVID has been referred to as a $3.5 Trillion challenge (David Cutler, Harvard Economist).
VIRLEXA GENE VECTOR , nhaled once, may bind to the same receptors as COVID and help block further infection. It may also program the lung epithelium to produce ensereptide, a natural peptide, which may help mitigate root causes of tissue damage and scarring during the acute phase of the infection,
The vector may also be given as an intramuscular injection,
which may enable production of ensereptide for many months and provide system wide protection against Long COVID affecting multiple organs,
SCARLEXA Gene Therapy, applied in the wound area after surgery or burn injuries, switches on the production of natural anti-scarring peptides, which have already been found to be safe and effective in clinical studies to date.
Rather than trying to apply topical treatment for weeks or months, one treatment with SCARLEXA turns on the production of the peptide at the site of the injury for many weeks or months.
See Investor Contacts:
THE NEXT BIG THING
Cellastra Inc 03/02/2023
Cellastra - An Overview
Cellastra Inc 01/31/2023
Virlexa in Long COVID
Learn about the $3.5 Trilliion Long COVID challenge
December 10, 2021